In the U.K., more pharma companies are now adopting country-specific social media.
New research found that follow-up studies of cancer drugs that won speedy approvals based on early results found most did not prolong or improve life in…
Now that Valeant's $10 billion talks to sell its Salix unit to Takeda have reportedly fallen through, the company is taking matters into its own hands.
Sen. Chuck Grassley is upset that Mylan's CEO was able to attend an industry conference despite declining an invitation to testify at his Senate hearing.
Drugmakers haven’t been shy this week about sharing their views on drug pricing. Thing is, they don’t all agree.
German drugmaker Boehringer Ingelheim has eliminated more than 240 jobs in the U.S. and is making cuts in Europe as well.
AbbVie and its development partners have big plans for the upcoming American Society of Hematology (ASH) meeting that starts Dec. 3.
Reversing a previous denial, the U.K.'s cost watchdogs have endorsed Merck's Keytruda for some patients with advanced lung cancer.
In this week's FiercePharmaAsia wrap-up, GSK China has a new leader, Japan's Opdivo price cut raises concerns in the country's regulatory…
As new flu vaccine technology emerges in the coming years, smaller players will have a shot at stealing market share.